Incyte Biosciences Distribution B.V.
SpainAll drugs from this manufacturer
-
It is used to treat adults with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who no longer respond to other treatments or who have a specific genetic mutation called T315I.
Dosage form: tablets, film-coated
Active substance Dosage ponatinib 15 mg -
It is used to treat adults with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who no longer respond to other treatments or who have a specific genetic mutation called T315I.
Dosage form: tablets, film-coated
Active substance Dosage ponatinib 30 mg -
It is used to treat adults with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who no longer respond to other treatments or who have a specific genetic mutation called T315I.
Dosage form: tablets
Active substance Dosage ponatinib 45 mg -
It is used to treat adults with certain blood cancers that affect B lymphocytes (diffuse large B-cell lymphoma and follicular lymphoma), specifically when the cancer has recurred or has not responded to previous treatments.
Dosage form: powder for concentrate for solution for infusion
Active substance Dosage tafasitamab 200 mg -
It is used on the skin to treat vitiligo affecting the face in adults and adolescents aged 12 years and older.
Dosage form: cream
Active substance Dosage ruxolitinib phosphate 1,98 g -
It is used to treat adults with bile duct cancer (cholangiocarcinoma) who have an abnormal form of the FGFR2 protein, especially when the cancer has spread to other parts of the body, cannot be operated on, or when other treatments no longer work.
Dosage form: tablets
Active substance Dosage pemigatinib 13,5 mg -
It is used to treat adults with bile duct cancer (cholangiocarcinoma) whose cancer cells have an abnormal form of the FGFR2 protein, especially when the cancer has spread to other parts of the body, cannot be removed by surgery, or when other treatments are no longer effective.
Dosage form: tablets
Active substance Dosage pemigatinib 4,5 mg -
It is used to treat adults with bile duct cancer (cholangiocarcinoma) whose cancer cells have an abnormal form of the FGFR2 protein, especially when the cancer has spread to other parts of the body, cannot be removed by surgery, or when other treatments are no longer effective.
Dosage form: tablets
Active substance Dosage pemigatinib 9 mg